Viewing Study NCT00216593

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:18 AM
Ignite Modification Date: 2026-01-25 @ 5:23 PM
Study NCT ID: NCT00216593
Status: COMPLETED
Last Update Posted: 2011-06-21
First Post: 2005-09-13
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
Sponsor: Janssen Pharmaceutica N.V., Belgium
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Dementia View
None Alzheimer Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None dementia View
None cognition function View
None Alzheimer disease View
None behavioral symptoms View
None galantamine hydrobromide View